Product Details for NDA 022264
INVEGA SUSTENNA (PALIPERIDONE PALMITATE)
39MG/0.25ML (39MG/0.25ML)
Marketing Status: Prescription
78MG/0.5ML (78MG/0.5ML)
Marketing Status: Prescription
117MG/0.75ML (117MG/0.75ML)
Marketing Status: Prescription
156MG/ML (156MG/ML)
Marketing Status: Prescription
234MG/1.5ML (156MG/ML)
Marketing Status: Prescription
39MG/0.25ML (39MG/0.25ML)
Marketing Status: Prescription
Active Ingredient: PALIPERIDONE PALMITATE
Proprietary Name: INVEGA SUSTENNA
Dosage Form; Route of Administration: SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR
Strength: 39MG/0.25ML (39MG/0.25ML)
Reference Listed Drug: Yes
Reference Standard: No
TE Code: AB
Application Number: N022264
Product Number: 001
Approval Date: Jul 31, 2009
Applicant Holder Full Name: JANSSEN PHARMACEUTICALS INC
Marketing Status: Prescription
Patent and Exclusivity Information
INVEGA SUSTENNA (PALIPERIDONE PALMITATE)
Proprietary Name: INVEGA SUSTENNA
Dosage Form; Route of Administration: SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR
Strength: 39MG/0.25ML (39MG/0.25ML)
Reference Listed Drug: Yes
Reference Standard: No
TE Code: AB
Application Number: N022264
Product Number: 001
Approval Date: Jul 31, 2009
Applicant Holder Full Name: JANSSEN PHARMACEUTICALS INC
Marketing Status: Prescription
Patent and Exclusivity Information
78MG/0.5ML (78MG/0.5ML)
Marketing Status: Prescription
Active Ingredient: PALIPERIDONE PALMITATE
Proprietary Name: INVEGA SUSTENNA
Dosage Form; Route of Administration: SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR
Strength: 78MG/0.5ML (78MG/0.5ML)
Reference Listed Drug: Yes
Reference Standard: No
TE Code: AB
Application Number: N022264
Product Number: 002
Approval Date: Jul 31, 2009
Applicant Holder Full Name: JANSSEN PHARMACEUTICALS INC
Marketing Status: Prescription
Patent and Exclusivity Information
INVEGA SUSTENNA (PALIPERIDONE PALMITATE)
Proprietary Name: INVEGA SUSTENNA
Dosage Form; Route of Administration: SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR
Strength: 78MG/0.5ML (78MG/0.5ML)
Reference Listed Drug: Yes
Reference Standard: No
TE Code: AB
Application Number: N022264
Product Number: 002
Approval Date: Jul 31, 2009
Applicant Holder Full Name: JANSSEN PHARMACEUTICALS INC
Marketing Status: Prescription
Patent and Exclusivity Information
117MG/0.75ML (117MG/0.75ML)
Marketing Status: Prescription
Active Ingredient: PALIPERIDONE PALMITATE
Proprietary Name: INVEGA SUSTENNA
Dosage Form; Route of Administration: SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR
Strength: 117MG/0.75ML (117MG/0.75ML)
Reference Listed Drug: Yes
Reference Standard: No
TE Code: AB
Application Number: N022264
Product Number: 003
Approval Date: Jul 31, 2009
Applicant Holder Full Name: JANSSEN PHARMACEUTICALS INC
Marketing Status: Prescription
Patent and Exclusivity Information
INVEGA SUSTENNA (PALIPERIDONE PALMITATE)
Proprietary Name: INVEGA SUSTENNA
Dosage Form; Route of Administration: SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR
Strength: 117MG/0.75ML (117MG/0.75ML)
Reference Listed Drug: Yes
Reference Standard: No
TE Code: AB
Application Number: N022264
Product Number: 003
Approval Date: Jul 31, 2009
Applicant Holder Full Name: JANSSEN PHARMACEUTICALS INC
Marketing Status: Prescription
Patent and Exclusivity Information
156MG/ML (156MG/ML)
Marketing Status: Prescription
Active Ingredient: PALIPERIDONE PALMITATE
Proprietary Name: INVEGA SUSTENNA
Dosage Form; Route of Administration: SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR
Strength: 156MG/ML (156MG/ML)
Reference Listed Drug: Yes
Reference Standard: Yes
TE Code: AB
Application Number: N022264
Product Number: 004
Approval Date: Jul 31, 2009
Applicant Holder Full Name: JANSSEN PHARMACEUTICALS INC
Marketing Status: Prescription
Patent and Exclusivity Information
INVEGA SUSTENNA (PALIPERIDONE PALMITATE)
Proprietary Name: INVEGA SUSTENNA
Dosage Form; Route of Administration: SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR
Strength: 156MG/ML (156MG/ML)
Reference Listed Drug: Yes
Reference Standard: Yes
TE Code: AB
Application Number: N022264
Product Number: 004
Approval Date: Jul 31, 2009
Applicant Holder Full Name: JANSSEN PHARMACEUTICALS INC
Marketing Status: Prescription
Patent and Exclusivity Information
234MG/1.5ML (156MG/ML)
Marketing Status: Prescription
Active Ingredient: PALIPERIDONE PALMITATE
Proprietary Name: INVEGA SUSTENNA
Dosage Form; Route of Administration: SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR
Strength: 234MG/1.5ML (156MG/ML)
Reference Listed Drug: Yes
Reference Standard: No
TE Code: AB
Application Number: N022264
Product Number: 005
Approval Date: Jul 31, 2009
Applicant Holder Full Name: JANSSEN PHARMACEUTICALS INC
Marketing Status: Prescription
Patent and Exclusivity Information
Proprietary Name: INVEGA SUSTENNA
Dosage Form; Route of Administration: SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR
Strength: 234MG/1.5ML (156MG/ML)
Reference Listed Drug: Yes
Reference Standard: No
TE Code: AB
Application Number: N022264
Product Number: 005
Approval Date: Jul 31, 2009
Applicant Holder Full Name: JANSSEN PHARMACEUTICALS INC
Marketing Status: Prescription
Patent and Exclusivity Information